Boston Scientific: Symetis Acquisition [Seeking Alpha]
Boston Scientific Corporation (BSX)
Last boston scientific corporation earnings: 4/29 06:30 am
Check Earnings Report
US:NYSE Investor Relations:
investors.bostonscientific.com
Company Research
Source: Seeking Alpha
Summary Quick Take Medical technology company Boston Scientific ( BSX ) has announced an agreement to acquire aortic valve medical device maker Symetis for $435 million in an all cash transaction. The global structural heart market is expected to grow rapidly, and Boston Scientific’s acquisition of Symetis promises to take full advantage of that growth opportunity. Target Company Ecublens, Switzerland-based Symetis was founded in 2001 by Simon Hoerstrup and Gregor Zund to develop minimally invasive aortic valve devices. Management is headed by current CEO Jacques Essinger, Ph.D., Chief Medical Officer Pedro Eerdmans and Chief Architect Jaroslaw Palka. The company’s portfolio includes two existing systems for treating patients with aortic valve stenosis: Acurate TA – heart Aortic valve replacement Acurate neo/TF valve – Femoral aortic valve replacement In addition, the company is currently in European clinical trials for its Acura
Show less
Read more
Impact Snapshot
Event Time:
BSX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BSX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BSX alerts
High impacting Boston Scientific Corporation news events
Weekly update
A roundup of the hottest topics
BSX
News
- Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Citigroup Inc. from $79.00 to $85.00. They now have a "buy" rating on the stock.MarketBeat
- Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at JPMorgan Chase & Co. from $72.00 to $82.00. They now have an "overweight" rating on the stock.MarketBeat
- Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $63.00 to $73.00. They now have a "hold" rating on the stock.MarketBeat
- Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Royal Bank of Canada from $78.00 to $82.00. They now have an "outperform" rating on the stock.MarketBeat
- Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Raymond James from $73.00 to $85.00. They now have a "strong-buy" rating on the stock.MarketBeat
BSX
Earnings
- 4/24/24 - Miss
BSX
Sec Filings
- 4/24/24 - Form 8-K
- 4/4/24 - Form 8-K
- 4/2/24 - Form 4
- BSX's page on the SEC website